Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Market Closed 02-14 16:00:00 EST

9.89

+1.24

+14.34%

盘后10.12

+0.23+2.36%

19:59 EST

High10.44	Low9.11	Vol9.08M
Open9.18	D1 Closing8.65	Amplitude15.33%
Mkt Cap725.25M	Tradable Cap528.16M	Total Shares73.33M
T/O89.43M	T/O Rate17.00%	Tradable Shares53.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":9.89,"timestamp":1739566800000,"preClose":8.65,"halted":0,"volume":9080598,"hourTrading":{"tag":"盘后","latestPrice":10.123,"preClose":9.89,"latestTime":"19:59 EST","volume":38141,"amount":377956.1979,"timestamp":1739581188134},"delay":0,"floatShares":53403260,"shares":73331690,"eps":-1.643455,"marketStatus":"Market Closed","change":1.24,"latestTime":"02-14 16:00:00 EST","open":9.175,"high":10.4362,"low":9.11,"amount":89431558.84791599,"amplitude":0.153318,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.643455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":8.65,"preHourTrading":{"tag":"盘前","latestPrice":9.1386,"preClose":8.65,"latestTime":"09:29 EST","volume":167498,"amount":1527443.4066519998,"timestamp":1739543353462},"postHourTrading":{"tag":"盘后","latestPrice":10.123,"preClose":9.89,"latestTime":"19:59 EST","volume":38141,"amount":377956.1979,"timestamp":1739581188134},"volumeRatio":3.51836065239949,"impliedVol":1.6716,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/MNMD/tweets","defaultTab":"tweets","newsList":[{"id":"2511996584","title":"RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.","url":"https://stock-news.laohu8.com/highlight/detail?id=2511996584","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511996584?lang=en_us&edition=fundamental","pubTime":"2025-02-13 02:25","pubTimestamp":1739384744,"startTime":"0","endTime":"0","summary":"The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/Stock-RobertFKennedyJr-02-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/Stock-RobertFKennedyJr-02-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/rfk-jr-senate-confirmation-hhs-secretary/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4588","BK4548","BK4533","BK4007","IE0009354923.USD","BK4139","BK4551","BK4168","CMPS","BK4585","MRNA","LU0053671581.USD","BK4532","BK4547","MNMD","BK4534","BK4568","CYBN","PCVX","BK4501"],"gpt_icon":1},{"id":"2509166242","title":"Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2509166242","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509166242?lang=en_us&edition=fundamental","pubTime":"2025-02-06 17:12","pubTimestamp":1738833143,"startTime":"0","endTime":"0","summary":"Shares in Mind Medicine ($MNMD) are surging, following a shift in market sentiment regarding possible growth and the potential of a significant app...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/mind-medicine-mnmd-advances-groundbreaking-lsd-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/mind-medicine-mnmd-advances-groundbreaking-lsd-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2509460109","title":"Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509460109","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509460109?lang=en_us&edition=fundamental","pubTime":"2025-02-05 02:37","pubTimestamp":1738694220,"startTime":"0","endTime":"0","summary":"Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and Human Services Department.The controversial nominee has previously said he believes psychedelic drugs could be useful therapeutics and should be decriminalized.Shares of Mind Medicine, the company better known as MindMed that is working on an LSD-based treatment for anxiety, were up 7.3% at $7.91 on Tuesday. Shares of Compass Pathways, which is developing a psilocybin product for depression, rose 9.9% to $4.74. Shares of ATAI Life Sciences, another developer of psychedelic therapies, surged 21% to $2.25.Kennedy has been a vocal skeptic of vaccines and repeatedly made false claims that they cause autism. He has refused to walk the claim back even at the urging of Sen. Bill Cassidy . Cassidy said he struggled with Kennedy's past comments on vaccines but nonetheless cast the deciding vote in favo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","BK4534","BK4533","BK4539","BK4551","BNTX","CMPS","MRNA","BK4535","PFE","BK4139","BK4548","NVAX","BK4588","BK4547","MNMD","BK4532","BK4007","BK4501","BK4568","BK4585"],"gpt_icon":1},{"id":"2507647561","title":"Mind Medicine doses first patient in Panorama study","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647561?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:20","pubTimestamp":1738239623,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-doses-first-patient-in-panorama-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-doses-first-patient-in-panorama-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2507644011","title":"Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2507644011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507644011?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA7LVYKH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2507164479","title":"MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of Mm120 in Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507164479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507164479?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA7LVYKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2507345642","title":"MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507345642","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507345642?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"The clinical trial design of the 52-week Panorama study is aligned to Voyage and will be conducted in two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel-group period; and Part B, a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT based on symptom severity. Participants will be randomized 2:1:2 to receive MM120 ODT 100 g, MM120 ODT 50 g, or placebo. The 50 g arm serves to confound participants’ ability to accurately assess the dose condition to which they have been randomized. This approach builds on the MM120 Phase 2b study, which the Company believes demonstrated that the clinical activity of MM120 was not attributable to functional unblinding and aligns with FDA guidance regarding the use of complementary designs across our Phase 2 and 3 studies. The primary endpoint of Panorama will measure the change from baseline in HAM-A at Week 12 between MM120 ODT 100 g and placebo, which is consistent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-120000222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ODT","BK4547","MNMD"],"gpt_icon":0},{"id":"2505282065","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2505282065","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505282065?lang=en_us&edition=fundamental","pubTime":"2025-01-20 23:48","pubTimestamp":1737388136,"startTime":"0","endTime":"0","summary":"Ascend Wellness secured $15 million to boost growth. Leafly Holdings transitioned to OTC trading after Nasdaq delisting. High Tide expanded into Germany with strategic acquisition. MindMed provided investor update with detailed plans for 2025 and beyond. Awakn secured unsecured credit facility to support research and development. Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.Cannabis multistate operator Ascend Wellness Holdings, Inc.   closed a $15 million private placement of senior secured notes, reinforcing its commitment to growth amid challenging market conditions. The notes, which were issued at 97% of their face value, carry a 12.75% interest rate and mature in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-154856336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","ABVC","BK4547","BK4183","MNQmain","BK4139","USJW.SI","NQmain","AAWH","BK4007","MNMD","QID","USAW.SI","TSYW.SI","HITI","PSQ","QLD",".IXIC","SQQQ","NVIW.SI"],"gpt_icon":1},{"id":"2493675167","title":"5 Biotech Breakthrough Stocks to Watch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493675167","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493675167?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:39","pubTimestamp":1734964740,"startTime":"0","endTime":"0","summary":"After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.Nonetheless, innovation is at its peak for the industry, with key spaces like diabetes/obesity, gene therapy, inflammation and neuroscience attracting investor attention. FDA approvals continued at a rapid pace throughout 2024. The FDA approved 46 drugs , which is in line with the annual average of 45 to 50 approvals. R&D innovation is likely to remain a major focus area in 2025 as well.In this article, we discuss five of the most enthralling biotech breakthrough stocks for those investors who are looking to diversify away from traditional pharmaceuticals. These stocks are Mind Medicine MNMD, Beam Therapeutics BEAM, Arcellx ACLX, Ocugen OCGN and Insmed INSM. These companies have novel pipeline candidate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-breakthrough-stocks-watch-143900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACLX","BK4139","INSM","BK4563","GAINI","BK4568","BK4547","ODT","BK4535","BK4007","BK4585","LU0320765992.SGD","LU0053671581.USD","LU0109394709.USD","MNMD","BEAM","BK4588","LU0889565916.HKD","BK4556","OCGN","BK4505"],"gpt_icon":0},{"id":"2492448974","title":"Chardan Initiates Coverage on Mind Medicine With Buy Rating, $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492448974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492448974?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:03","pubTimestamp":1734699818,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) has an average rating of Buy and mean price target of $26.63, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNMD"],"gpt_icon":0},{"id":"2492416409","title":"Mind Medicine initiated with a Buy at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2492416409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492416409?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:11","pubTimestamp":1734693063,"startTime":"0","endTime":"0","summary":"Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead asset ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-initiated-with-a-buy-at-chardan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-initiated-with-a-buy-at-chardan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2492170085","title":"Mind Medicine to Join Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492170085","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492170085?lang=en_us&edition=fundamental","pubTime":"2024-12-19 23:55","pubTimestamp":1734623720,"startTime":"0","endTime":"0","summary":"Mind Medicine  said Thursday that it is set to join the Nasdaq Biotechnology Index on Monday.Companies are selected annually in December for the Nasdaq Biotechnology Index based on specific eligibility criteria, including their classification as biotechnology or pharmaceutical companies under the Industry Classification Benchmark, according to Mind Medicine.Price: 7.24, Change: +0.01, Percent Change: +0.14","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNQmain","QLD","QID","BK4112","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","USJW.SI","USAW.SI","BK4007","MNMD","BK4547",".IXIC","IE00B3QW5Z07.USD","LU2095319765.USD","NQmain","PSQ","IE00BKPKM429.USD","NVIW.SI","BK4588","TQQQ","SQQQ","LU2210149790.SGD","LU2210150020.SGD","TSYW.SI","NDAQ"],"gpt_icon":1},{"id":"2492124149","title":"Mind Medicine to be added to Nasdaq Biotechnology Index December 23.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492124149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492124149?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:25","pubTimestamp":1734611128,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-to-be-added-to-nasdaq-biotechnology-index-december-23?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-to-be-added-to-nasdaq-biotechnology-index-december-23?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","QQQ","LU2210150020.SGD","BK4547","PSQ","USJW.SI","TSYW.SI","QID","BK4007","MNQmain","BK4585","NQmain","QLD","TQQQ","NVIW.SI","MNMD","BK4588","LU2210149790.SGD","BK4112",".IXIC","USAW.SI","SQQQ","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2492833121","title":"MindMed to Be Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492833121","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492833121?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"NEW YORK, December 19, 2024----Mind Medicine  Inc. , , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index , effective at market open on Monday, December 23, 2024.\"2024 has been a transformational year for MindMed. We’ve successfully executed many important milestones, including raising approximately $250 million through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet  and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for major depressive disorder, and most recently, launching Voyage, our Phase 3 study of MM120 ODT in generalized anxiety disorder,\" said Rob Barrow, Chief Executive Officer of MindMed. \"We are in a pivotal phase in our growth and the addition to the NBI further validates our potential in delivering long-term value to shareholders as we p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eWlU2A18DIV5.Fny3k24ng--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/387f6e4e380da4e39f13a8e92f42a101","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eWlU2A18DIV5.Fny3k24ng--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/387f6e4e380da4e39f13a8e92f42a101"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-added-nasdaq-biotechnology-index-120000637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","IE00BKPKM429.USD","QID","LU2095319765.USD","NVIW.SI","BK4007","ODT","MNMD","LU2210150020.SGD","NQmain","PSQ","TQQQ","QLD",".IXIC","ICB","BK4588","NDAQ","TSYW.SI","BK4112","IE00B64PRP62.GBP","MNQmain","SQQQ","BK4585","BK4547","USAW.SI","USJW.SI","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2492719962","title":"Mind Medicine Price Target Maintained With a $20.00/Share by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492719962","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492719962?lang=en_us&edition=fundamental","pubTime":"2024-12-18 00:21","pubTimestamp":1734452460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 11:21 ET (16:21 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","OPY"],"gpt_icon":0},{"id":"2492432951","title":"Mind Medicine (MNMD) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492432951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492432951?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:45","pubTimestamp":1734439523,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mind-medicine-mnmd-receives-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mind-medicine-mnmd-receives-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","MNMD","BK4547","BK4007","OPY"],"gpt_icon":0},{"id":"2492560610","title":"MindMed Begins Phase 3 LSD Study for Anxiety","url":"https://stock-news.laohu8.com/highlight/detail?id=2492560610","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492560610?lang=en_us&edition=fundamental","pubTime":"2024-12-17 01:41","pubTimestamp":1734370869,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) has released an update. Mind Medicine has commenced its Phase 3 Voyage study, dosing the first patient with MM120, an optimize...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindmed-begins-phase-3-lsd-study-for-anxiety?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindmed-begins-phase-3-lsd-study-for-anxiety?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4007","BK4547"],"gpt_icon":0},{"id":"2491660696","title":"Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660696","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660696?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:35","pubTimestamp":1734356145,"startTime":"0","endTime":"0","summary":"Mind Medicine  said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder.The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo. Mind Medicine said the second study, called Panorama, will be conducted in the US and Europe and is expected to be initiated in H1 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2491745660","title":"BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Voyage Study Of Mm120 In Generalized Anxiety Disorder (Gad)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491745660","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491745660?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:36","pubTimestamp":1734352566,"startTime":"0","endTime":"0","summary":"BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Voyage Study Of Mm120 In Generalized Anxiety Disorder (Gad)Dec 16 (Reuters) - Mind Medicine (MindMed) Inc MNMD.O:MINDMED ANNOUNCES FIRST PATIENT ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUA3MXVHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2491366741","title":"Mind Med: First patient dosed in Voyage study of LSD in treatment of GAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2491366741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491366741?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:10","pubTimestamp":1734351012,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-med-first-patient-dosed-in-voyage-study-of-lsd-in-treatment-of-gad?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-med-first-patient-dosed-in-voyage-study-of-lsd-in-treatment-of-gad?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":0.1973},{"period":"1month","weight":0.463},{"period":"3month","weight":0.2745},{"period":"6month","weight":0.555},{"period":"1year","weight":1.1594},{"period":"ytd","weight":0.421}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.097954},{"month":2,"riseRate":1,"avgChangeRate":0.27933},{"month":3,"riseRate":0.333333,"avgChangeRate":0.135594},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.020489},{"month":5,"riseRate":0.25,"avgChangeRate":-0.037122},{"month":6,"riseRate":0.5,"avgChangeRate":-0.112493},{"month":7,"riseRate":0.75,"avgChangeRate":0.159384},{"month":8,"riseRate":0.25,"avgChangeRate":-0.108659},{"month":9,"riseRate":0,"avgChangeRate":-0.300494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.039054},{"month":11,"riseRate":0.5,"avgChangeRate":0.060477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.119824}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction